Gross margin in the range of 70% to 71%, up from previous guidance range of 68% to 70%.
RxSight Now Sees FY24 Revenue At The Top Of Previously Provided Guidance Range Of $139M - $140M, Est $139.642M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.